21571-52-8

Basic information

• Product Name: Benzene, 2,4-dibromo-1-(methoxymethoxy)-
• CAS NO: 21571-52-8
• Molecular Formula: C8H8Br2O2
• Molecular Weight: 295.958
• Mol File: 21571-52-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzene, 2,4-dibromo-1-(methoxymethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 2,4-dibromo-1-(methoxymethoxy)-(21571-52-8)
• EPA Substance Registry System: Benzene, 2,4-dibromo-1-(methoxymethoxy)-(21571-52-8)

Safety Data

• Hazardous Substances Data: 21571-52-8(Hazardous Substances Data)

Upstream product

• 615-58-7 2,4-dibromophenol 
• 3188-13-4 ethyl chloromethyl ether 
• 109-87-5 Dimethoxymethane 
• 121-44-8 triethylamine 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 1335218-47-7 ethyl 2-(5-bromo-2-(methoxymethoxy)phenyl)-2-oxoacetate 
• 1335218-48-8 (S)-ethyl 2-(5-bromo-2-(methoxymethoxy)phenyl)-2-(tert-butylsulfinylimino)acetate 
• 90-15-3 α-naphthol 
• 162267-12-1 (Z)-2-[5-bromo-α-(tert-butoxyimino)-2-hydroxybenzyl]-3-hydroxypyridine 
• 160538-97-6 5-bromo-8-(methoxymethoxy)-3-methyl-1-naphthalenol 
• 162269-55-8 2-(5-bromo-2-hydroxybenzoyl)-3-hydroxypyridine 

Relevant articles and documents

AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Synthesis and biological activity of novel 2-(α- alkoxyimino)benzylpyridine derivatives as K+ channel openers

The search for novel K+ channel openers with a non-benzopyran skeleton, unlike cromakalim, led to the discovery of a new series of (Z)-2-(α- alkoxyimino)benzylpyridine derivatives. Synthesis was achieved by using a (Z)-dominant condensation reaction of henzoylpyridines with O- alkylhydroxylamines, followed by m-chloroperhenzoic acid (m-CPBA) oxidation. The compounds were tested for their vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2- and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for their effects on the coronary blood flow (CBF) after intracoronary injection in anesthetized dogs. A large number of the 2-(α- alkoxyimino)benzylpyridines strongly inhibited TEA and BaCl2-induced contraction, had no effect on 80 mM KCl-induced contraction, and increased the CBF to more than 200% of the basal flow at 10-30μg/dog. In particular, (Z)-2-[5-bromo-α-(tert-butoxyimino)-4-fluoro-2-hydroxybenzyl]-3- hydroxypyridine 1-oxide (7d) showed highly potent vasorelaxant activity (EC50=0.28μM) comparable to that of levcromakalim (EC50=0.17 μM), and gave a significantly longer-lasting increase (T ( 1/4 ) = 30 min) in the CBF compared to levcromakalim, nicorandil, nitroglycerin, or diltiazem (T( 1/4 )=5.2, 0.9, 0.4, and 2.2 min, respectively). It also exhibited a stable and long-lasting hypotensive effect (over 7h) upon oral administration of 1 mg/kg in spontaneously hypertensive rats (SHRs).